- |||||||||| AC0682 / Accutar Biotech
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer (clinicaltrials.gov) - Apr 11, 2024
P1, N=21, Terminated,
N=30 --> 21 | Trial completion date: Dec 2024 --> Apr 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Apr 2024; Voluntarily terminate the study since the sponsor's development strategy was adjusted.
- |||||||||| AC0682 / Accutar Biotech
Trial completion date, Trial primary completion date, Metastases: A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer (clinicaltrials.gov) - Apr 4, 2024
P1, N=30, Active, not recruiting,
N=30 --> 21 | Trial completion date: Dec 2024 --> Apr 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Apr 2024; Voluntarily terminate the study since the sponsor's development strategy was adjusted. Trial completion date: Feb 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Dec 2024
- |||||||||| AC0682 / Accutar Biotech
Trial completion date, Trial termination, Metastases: A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 24, 2024
P1, N=6, Terminated,
Trial completion date: Feb 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Dec 2024 Trial completion date: Dec 2024 --> Sep 2023 | Active, not recruiting --> Terminated; Voluntarily terminate the study since the sponsor's development strategy was adjusted.
- |||||||||| AC0682 / Accutar Biotech
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Oct 26, 2023
P1, N=6, Active, not recruiting,
Trial completion date: Dec 2024 --> Sep 2023 | Active, not recruiting --> Terminated; Voluntarily terminate the study since the sponsor's development strategy was adjusted. Recruiting --> Active, not recruiting | N=150 --> 6 | Trial primary completion date: Jul 2023 --> Dec 2023
- |||||||||| AC0682 / Accutar Biotech
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer (clinicaltrials.gov) - Oct 25, 2023
P1, N=30, Active, not recruiting,
Recruiting --> Active, not recruiting | N=150 --> 6 | Trial primary completion date: Jul 2023 --> Dec 2023 Recruiting --> Active, not recruiting | Trial completion date: Sep 2023 --> Feb 2024 | Trial primary completion date: Jun 2023 --> Jan 2024
|
